Gilead Sciences, Inc. (NASDAQ:GILD)‘s stock had its “buy” rating restated by equities research analysts at Deutsche Bank AG in a research report issued on Thursday. They presently have a $81.00 price target on the biopharmaceutical company’s stock. Deutsche Bank AG’s price target indicates a potential downside of 3.28% from the stock’s previous close.

Several other research analysts have also recently issued reports on the stock. William Blair reissued an “outperform” rating and set a $87.00 target price on shares of Gilead Sciences in a report on Thursday. Argus raised shares of Gilead Sciences from a “hold” rating to a “buy” rating and set a $100.00 target price for the company in a report on Thursday. Berenberg Bank set a $86.00 target price on shares of Gilead Sciences and gave the stock a “buy” rating in a report on Tuesday. Needham & Company LLC reissued a “hold” rating on shares of Gilead Sciences in a report on Monday, August 28th. Finally, Robert W. Baird reissued an “outperform” rating and set a $87.00 target price on shares of Gilead Sciences in a report on Tuesday. Twelve equities research analysts have rated the stock with a hold rating and nineteen have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and a consensus price target of $82.26.

Shares of Gilead Sciences (NASDAQ:GILD) opened at 83.75 on Thursday. The stock has a market capitalization of $109.37 billion, a price-to-earnings ratio of 9.10 and a beta of 1.18. The stock has a 50 day moving average price of $74.38 and a 200 day moving average price of $69.29. Gilead Sciences has a 1-year low of $63.76 and a 1-year high of $84.13.

Gilead Sciences (NASDAQ:GILD) last issued its earnings results on Wednesday, July 26th. The biopharmaceutical company reported $2.56 earnings per share (EPS) for the quarter, topping the Thomson Reuters’ consensus estimate of $2.11 by $0.45. Gilead Sciences had a net margin of 42.90% and a return on equity of 66.07%. The firm had revenue of $7.14 billion during the quarter, compared to analysts’ expectations of $6.35 billion. During the same quarter last year, the company posted $3.08 earnings per share. The firm’s revenue was down 8.2% compared to the same quarter last year. Equities research analysts anticipate that Gilead Sciences will post $8.73 EPS for the current year.

WARNING: “Gilead Sciences, Inc. (GILD) Stock Rating Reaffirmed by Deutsche Bank AG” was originally published by The Cerbat Gem and is the property of of The Cerbat Gem. If you are accessing this article on another domain, it was illegally stolen and republished in violation of U.S. & international copyright and trademark law. The correct version of this article can be accessed at https://www.thecerbatgem.com/2017/09/02/gilead-sciences-inc-gild-stock-rating-reaffirmed-by-deutsche-bank-ag.html.

In other news, EVP Gregg H. Alton sold 5,000 shares of the company’s stock in a transaction that occurred on Monday, July 3rd. The shares were sold at an average price of $71.06, for a total value of $355,300.00. Following the transaction, the executive vice president now directly owns 102,988 shares in the company, valued at approximately $7,318,327.28. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, insider John C. Martin sold 73,333 shares of the company’s stock in a transaction that occurred on Monday, July 3rd. The stock was sold at an average price of $71.00, for a total transaction of $5,206,643.00. Following the completion of the transaction, the insider now owns 3,199,969 shares in the company, valued at $227,197,799. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 256,666 shares of company stock worth $19,173,184. Company insiders own 1.30% of the company’s stock.

Several institutional investors have recently modified their holdings of the company. Hall Laurie J Trustee raised its position in shares of Gilead Sciences by 20.0% in the first quarter. Hall Laurie J Trustee now owns 1,500 shares of the biopharmaceutical company’s stock valued at $100,000 after buying an additional 250 shares in the last quarter. Harel Insurance Investments & Financial Services Ltd. raised its position in shares of Gilead Sciences by 583.3% in the first quarter. Harel Insurance Investments & Financial Services Ltd. now owns 1,640 shares of the biopharmaceutical company’s stock valued at $110,000 after buying an additional 1,400 shares in the last quarter. Dubuque Bank & Trust Co. raised its position in shares of Gilead Sciences by 19.4% in the first quarter. Dubuque Bank & Trust Co. now owns 1,642 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 267 shares in the last quarter. Penserra Capital Management LLC raised its position in shares of Gilead Sciences by 9.5% in the first quarter. Penserra Capital Management LLC now owns 1,656 shares of the biopharmaceutical company’s stock valued at $112,000 after buying an additional 144 shares in the last quarter. Finally, Webster Bank N. A. raised its position in shares of Gilead Sciences by 51.7% in the first quarter. Webster Bank N. A. now owns 1,831 shares of the biopharmaceutical company’s stock valued at $125,000 after buying an additional 624 shares in the last quarter. Hedge funds and other institutional investors own 74.04% of the company’s stock.

About Gilead Sciences

Gilead Sciences, Inc is a research-based biopharmaceutical company that discovers, develops and commercializes medicines in areas of unmet medical need. The Company’s portfolio of products and pipeline of investigational drugs includes treatments for Human Immunodeficiency Virus/Acquired Immune Deficiency Syndrome (HIV/AIDS), liver diseases, cancer, inflammatory and respiratory diseases and cardiovascular conditions.

Analyst Recommendations for Gilead Sciences (NASDAQ:GILD)

Receive News & Stock Ratings for Gilead Sciences Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Gilead Sciences Inc. and related stocks with our FREE daily email newsletter.